About the Company
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
The company believes that better and earlier detection of cancer through liquid biopsies will:
Improve patient outcomes
Increase the life expectancy of cancer patients
Significantly reduce health care costs
Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.
Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:
OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need
OncoCyte Analytical Validation Study of its Lung Cancer Diagnostic Test Confirms Previously Published Results
– Abstract to Present Complete Study Findings Submitted to a Scientific Conference – – Final Stage of Development Commences- ALAMEDA, Calif., July 24, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to...
ALAMEDA, Calif., June 26, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been added to the broad U.S. market Russell 3000® Index and...